From: Two independent epigenetic biomarkers predict survival in neuroblastoma
INRG staging system | |||||
---|---|---|---|---|---|
Characteristics | L1 | L2 | M | MS | Total |
Number of patients | 12 | 21 | 42 | 8 | 83 |
Patients over 18 months at diagnostic | 3 | 8 | 38 | 0 | 49 |
Sex | |||||
Female | 8 | 6 | 16 | 3 | 33 |
Male | 4 | 15 | 26 | 5 | 50 |
MYCN status | |||||
Amplified (%) | 0 | 8 (38%) | 16 (38%) | 1 (12.5%) | 25 (30%) |
Not amplified (%) | 12 (100%) | 13 (62%) | 23 (55%) | 7 (87.5%) | 55 (66%) |
Not determined (%) | 0 | 0 | 3 (7%) | 0 | 3 (4%) |
Patients with relapse (%) | 3 (25%) | 5 (24%) | 22 (52%) | 0 | 30 (36%) |
Dead (%) | 0 | 6 (29%) | 25 (60%) | 0 | 31 (37%) |